服务热线

15021010459
技术文章
当前位置:主页 > 技术文章 > Ariad抗癌药Iclusig重返市场

Ariad抗癌药Iclusig重返市场

更新时间:2014-01-20 点击次数:1406

    去年Ariad Pharmaceuticals公司业绩由于主打抗癌药物Iclusig被紧急下架而遭受重创。公司一度陷入困境并将其在美国的员工裁员160人,约占美 国分部总员工数的40%,以节省开支。不过现在Ariad Pharmaceuticals公司迎来一丝曙光。公司已经着手将Iclusig重新推向市场。此次Ariad将把Iclusig的适用症范围缩小,并在 药物包装上标明可能出现的副作用如心脏病、血液凝块等。不过由于Iclusig适用范围变小,公司的收入可能也会大受影响。为解决这一问题公司计划申请重 启此前被FDA下令暂停的关于Iclusig治疗慢性白血病的研究计划以达到亡羊补牢的作用。

    不过Ariad Pharmaceuticals公司的这一系列举措能否获得预期效果还需要等待公司2014年*季度财报公布后才能知晓。

详细英文报道:

    Last year, Ariad Pharmaceuticals ($ARIA) watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

    The drug is now indicated for a smaller group of leukemia patients than before, and it carries a serious boxed warning about the risk of clotting and heart failure that got it pulled from shelves in the fall. But it is for sale, and that puts Ariad in a better place than many predicted at its nadir.

    "We are back on track," CEO Harvey Berger told Bloomberg last month. "We'll enter 2014 largely where we were as we started off the fall in September."

    Of course, that's not entirely the case. Losing more than half of its value forced Ariad to considerably thin its ranks, laying off 40% of its U.S. workforce--or 160 employees--in an effort to save $26 million. Now the company plans to gradually ramp up stateside sales with the help of specialty pharmacy Biologics, Inc., first looking to transition the case-by-case patients who were still using the drug during its marketing hiatus.

    And the company has a long way to go on the R&D side. When the storm over Iclusig began, Ariad was in the process of testing the drug in a broader population, but an FDA-imposed clinical hold led the company to discontinue a Phase III study on patients with newly diagnosed chronic myeloid leukemia and put the brakes on a fleet of Phase II studies designed to expand the drug's market. Berger has said that Ariad is yet to decide just how to move forward with its paused programs.

    Still, the biotech is undeniably sitting prettier than it was just two months ago, and its next big test will come when Q1 sales figures roll in.——(华雅干细胞整理报道)

2024 版权所有 © 重庆市华雅干细胞技术有限公司  备案号:渝ICP备14000349号-4 sitemap.xml 管理登陆 技术支持:化工仪器网

地址:重庆市江北区金渝大道153号8栋20-14 传真:023-63419626 邮件:sales@ys-bio.com

重庆市华雅干细胞技术有限公司主要经营干细胞研究 干细胞治疗产品 生物试剂 实验耗材 药物研发等产品。

关注我们

服务热线

400-021-2200

扫一扫,关注我们

Baidu
map